Table 3.
Time above protective PPQ concentrations by adherence status and weight for age z-score at the time of most recent DP course.
| % Time above protective PPQ levels, (2.5–97.5% of population) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Regimen | Full adherence | 2/3 adherence | 1/3 adherence | ||||||
| WAZ ≤ −2 | WAZ > −2 | Percentage of children with >80% time above 15.4 ng/mL | WAZ ≤ −2 | WAZ > −2 | Percentage of children with >80% time above 15.4 ng/mL | WAZ ≤ −2 | WAZ > −2 | Percentage of children with >80% time above 15.4 ng/mL | |
| Every 4-week DP | |||||||||
| Clinical trial protocol | 67.3 (14.2–100) | 92.4 (19.2–100) | 56.6 (54.4–58.8) | 36.7 (8.8–100) | 60.1 (11.9–100) | 35.8 (32.4–39.5) | 16.4 (3.9–98.7) | 23.9 (5.4–100) | 12.0 (10.2–14.3) |
| WHO 2015 | 84.6 (18.0–100) | 100 (29.8–100) | 74.5 (72.3–76.5) | 50.1 (11.1–100) | 86.0 (17.5–100) | 51.1 (48.9–53.3) | 20.8 (5.0–100) | 37.7 (8.0–100) | 21.2 (19.5–23.0) |
| Proposed age-based | 100 (28.9–100) | 100 (35.9–100) | 81.3 (79.4–83.1) | 81.9 (17.8–100) | 94.4 (20.6–100) | 59.5 (57.3–61.8) | 35.0 (7.9–100) | 45.4 (9.4–100) | 26.2 (24.4–28.2) |
| Every 8-week DP | |||||||||
| Clinical trial protocol | 19.7 (6.0–78.5) | 28.4 (7.8–96.3) | 6.3 (5.3–7.4) | 11.5 (3.8–54.8) | 15.9 (5.0–73.3) | 1.6 (1.1–2.1) | 6.2 (1.8–25.7) | 7.8 (2.4–39.4) | 0.1 (<0.01–0.3) |
| WHO 2015 | 26.3 (7.4–91.0) | 45.9 (11.4–100) | 15.4 (13.8–17.1) | 14.9 (4.8–69.3) | 26.5 (7.2–94.3) | 5.3 (4.4–6.3) | 7.7 (2.3–36.0) | 12.0 (3.6-62.0) | 0.7 (0.4–1.0) |
| Proposed age-based | 42.0 (11.2–100) | 50.9 (12.8–100) | 18.9 (17.0–20.7) | 24.5 (7.2–86.9) | 29.4 (8.1–95.7) | 6.5 (5.4–7.6) | 11.6 (3.5–55.6) | 13.4 (4.0–65.4) | 0.9 (0.5–1.2) |
WAZ weight-for-age z-score.
Clinical trial protocol: <6 kg: DHA/PPQ 10/80 mg daily × 3 days, 6–<11 kg: DHA/PPQ 20/160 mg daily × 3 days, 11–<15 kg: DHA/PPQ 30/240 mg daily × 3 days, 15–<20 kg: DHA/PPQ 40/320 mg daily × 3 days.
World Health Organization (WHO) 2015: <8 kg: DHA/PPQ 20/160 mg daily × 3 days, 8–<11 kg: DHA/PPQ 30/240 mg daily × 3 days, 11–<17 kg: DHA/PPQ 40/320 mg daily × 3 days, 17–<25 kg: DHA/PPQ 50/480 mg daily × 3 days.
Proposed age-based: 2–6 months of age: DHA/PPQ 20/160 mg daily × 3 days, 6–18 months of age: DHA/PPQ 30/240 mg daily × 3 days, 18–24 months of age: DHA/PPQ 40/320 mg daily × 3 days.